Study Highlights
- The genomic landscape of high versus low TACSTD2 expressors varied widely by cancer type.
- Significant but small difference in TACSTD2 expression was observed between primary and metastatic sites.
- There was an increased prevalence of T Cellinflamed tumors in the top quartile of TACSTD2 expressors across investigated tumor types.
- High expression of TACSTD2 was associated with worse overall survival in Breast, CRC and PDAC tumors.
Conclusion
- The association of TACSTD2 expression with KRAS, TP53 and ARID1A mutations and T cell inflamed tumors (ICI responsive) should be considered as possible combination therapies with TROP2 targeting antibody drug conjugates.